Phaseline

Companies › Greenwich LifeSciences

Greenwich LifeSciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Dec 2031.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GLSI-100
HER2/Neu peptide vaccine with GM-CSF adjuvant
ERBB2Phase 3Breast CancerDec 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05232916GLSI-100Phase 3Breast CancerOncologyDec 2031

From the company's SEC filings

Cash of $9m on 2026-06-30; operating cash outflow about $13m a year; runway about 8 months at that burn, to Feb 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway

Targets

ERBB2 (1)

Companies with the same targets

Beijing Biotech Roche Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical Suzhou Suncadia Biopharmaceuticals Pfizer Sichuan Baili Pharmaceutical Shanghai Henlius Biotech Chia Tai Tianqing Pharmaceutical Group Yuhan

Companies built like this

Shanghai Miracogen 3D Medicines (Sichuan) PharmaEssentia Partner Therapeutics Abscint NV/SA

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.